GlassScriptPhysician profile
Mohammad Afzal
NPI 1669411161
$1,670.47
in general payments reported to CMS, 2019-2025
22 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $177 · 2021: $499 · 2022: $156 · 2023: $162 · 2024: $139 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $449 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $448.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $513.14 | 2019-2023 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $129.66 | 2019-2022 | |
| Pfizer INC. | $110.51 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $99.00 | 2021-2025 | Qelbree, Qelbree |
| Cranial Technologies, INC | $89.82 | 2019-2025 | Doc Band |
| Vanda Pharmaceuticals INC. | $88.00 | 2024 | Fanapt, Hetlioz |
| Ironshore Pharmaceuticals INC. | $79.78 | 2019-2022 | |
| Ars Pharmaceuticals Operations, INC. | $73.30 | 2025 | Neffy |
| Glaxosmithkline, LLC. | $72.97 | 2019-2022 | |
| Sanofi Pasteur INC. | $51.72 | 2021-2022 | |
| Eko Health, INC. | $50.00 | 2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.13 | 2025 | Caplyta |
| Abbvie INC. | $38.82 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $36.68 | 2022-2024 | Vaqta, Gardasil 9, Gardasil |
| Novartis Pharmaceuticals Corporation | $36.52 | 2023 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $31.27 | 2025 | Auvelity |
| Abbott Laboratories | $30.41 | 2021 | |
| Ucb, INC. | $28.73 | 2024 | Briviact |
| Meridian Bioscience INC. | $22.58 | 2019 | |
| Adlon Therapeutics L.P. | $17.76 | 2021 | |
| Genentech USA, INC. | $16.12 | 2019 | |
| Collegium Pharmaceutical, INC. | $13.55 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Afzal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.